Recent Updates
Recently added Catalysts
PRLD Positive Sentiment Score: 70/100

Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia

Wednesday, July 22, 2026 1 min read
Key Takeaway: The article discusses the development of precision degrader-antibody conjugates (pDACs) targeting SMARCA2/4 as a novel therapeutic approach for acute myeloid leukemia. This innovative strategy aims to enhance treatment efficacy and specificity in targeting cancer cells. The research highlights the potential benefits of this dual payload mechanism in improving patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of innovative pDACs for targeted therapy.
  • Potential to improve treatment outcomes for acute myeloid leukemia.
  • Focus on dual payload targeting SMARCA2/4 enhances therapeutic specificity.

Full Press Release Details

Ryan Holmes, Andrew Moore, Max Foroutan, Jake Karwoski, Alex Grego, Carly Bachner1 Neha Bhagawat, Corey Basch, Soham Maity, Chun Chen, Sarah B. Pawley, Vijay Devannah, Sina Rezazadeh, Ross Kuskovsky, Joseph Rager, Kenneth Ray, Kirsten Gallagher, Yue Zou, Koichi Ito, Diane Heiser, Sang Hyun Lee, Peggy Scherle , Andrew P. Combs, Andrew W. Buesking
The post Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 dual payload as targeted therapeutics for acute myeloid leukemia appeared first on Prelude Therapeutics .

Frequently Asked Questions

What are precision degrader-antibody conjugates?

Precision degrader-antibody conjugates (pDACs) are innovative therapeutics designed to target specific cancer cells.

How do pDACs target acute myeloid leukemia?

pDACs target acute myeloid leukemia by utilizing a dual payload mechanism focused on SMARCA2/4.

What is the significance of SMARCA2/4 in cancer therapy?

SMARCA2/4 are critical targets that enhance the specificity and efficacy of cancer treatments.

Who are the authors of the study on pDACs?

The study is authored by Ryan Holmes, Andrew Moore, and several other researchers.

Tags: PRLD Viatris Investor Conferences Healthcare pDACs SMARCA2 SMARCA4 acute myeloid leukemia targeted therapy
Last updated: Jul 22, 2026

Biotech snapshot

Cash runway
$82M liquidity · $7M/mo burn
~9 mo
Medium dilution risk
Lead asset
PRT3789Phase 1
Advanced Solid Tumor →